CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02595983
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:20.840449+00:00
Published At: 2019-03-28T00:00:00+00:00
Record Updated At: 2019-03-28
Results Posted At: 2019-03-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Transthyretin (TTR)-Mediated Amyloidosis", "Familial Amyloidotic Polyneuropathy (FAP)", "ATTR Amyloidosis", "Familial Amyloid Neuropathies"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-03-28"
protocolSection.identificationModule.nctId: "NCT02595983"
protocolSection.identificationModule.officialTitle: "An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-03-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.